Basic Information
| LncRNA/CircRNA Name | CASC11 |
| Synonyms | NA |
| Region | GRCh38_8:127686343-127733967 |
| Ensemble | ENSG00000249375 |
| Refseq | NR_117101 |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | lung cancer |
| ICD-0-3 | C34 |
| Methods | qPCR, Western blot, Luciferase reporter assay |
| Sample | Lung mucosal cell lines (16HBE), lung cancer cell lines (A549, H157 and SPC-A-1), lung cancer tissues and paracancerous tissues |
| Expression Pattern | up-regulated |
| Function Description | CASC11 and CDK1 were highly expressed, whereas microRNA-302 was lowly expressed in lung cancer tissues. Identically, CASC11 was highly expressed in lung cancer cell lines (A547, H157 and SPC-A-1) than controls as well. CASC11 knockdown attenuated proliferative capacity of lung cancer cells. The opposite trend was observed by microRNA-302 knockdown. Dual-luciferase reporter gene assay verified that CASC11 could bind to microRNA-302 and microRNA-302 could bind to CDK1. CDK1 expression in lung cancer cells was negatively regulated by CASC11. MicroRNA-302 knockdown reversed the inhibitory effect of CASC11 on CDK1 expression. The proliferation of lung cancer cells co-transfected with microRNA-302 inhibitor and si-CASC11 decreased compared with those transfected with microRNA-302 inhibitor. |
| Pubmed ID | 31378894 |
| Year | 2019 |
| Title | LncRNA CASC11 promotes the development of lung cancer through targeting microRNA-302/CDK1 axis |
External Links
| Links for CASC11 | GenBank HGNC NONCODE |
| Links for lung cancer | OMIM COSMIC |